
Fidson, led by Fidelis Ayebae, declares $1.49 million dividend for shareholders
The payout reflects the pharmaceutical group’s focus on rewarding investors following an impressive financial performance in 2024.
The payout reflects the pharmaceutical group’s focus on rewarding investors following an impressive financial performance in 2024.
This growth was driven by a surge in sales of ethical and OTC products, reinforcing Fidson’s position as a top player in Nigeria’s pharmaceutical industry.
The collaboration with NEXIM is expected to position Fidson for a stronger presence in Africa's rapidly expanding pharmaceutical market.
This move aligns with the company’s efforts to bolster Nigeria’s self-sufficiency in healthcare, focusing on combating the country's ongoing HIV crisis.
The deal is part of a broader initiative to enhance self-sufficiency in Africa’s healthcare infrastructure, particularly in the battle against HIV.
The surge in revenue is linked to the heightened sales of ethical products, including infusions, capsules, and tablets.
Ayebae, a banker turned accomplished industrialist, owns a 33.1-percent stake in the pharmaceutical company, which translates to 759,643,749 ordinary shares.
The recent gains solidify Ayebae’s position as one of Africa’s pharmaceutical industry magnates.
Ayebae owns an impressive 33.1-percent stake in Fidson Healthcare.
Under Ayebae’s guidance, Fidson Healthcare has achieved exceptional financial growth, reporting a significant increase in profits for the 2022 fiscal year.
Fidson Healthcare has established itself as a leading player in the Nigerian and West African pharmaceutical industries.